{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:49:15Z","timestamp":1790138955881,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.clbc.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T11:55:29Z","timestamp":1680004529000},"page":"454-460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9268-7070","authenticated-orcid":false,"given":"Nicole M. Grogan","family":"Fleege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley M.","family":"Kidwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clbc.2023.03.009_bib0001","article-title":"Ovarian function suppression in premenopausal women with early-stage breast cancer","volume":"18","author":"Lambertini","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0002","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","article-title":"Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials","volume":"369","author":"Cuzick","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2023.03.009_bib0003","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1998.16.3.994","article-title":"Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study","volume":"16","author":"Taylor","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0004","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.18.01967","article-title":"Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT","volume":"38","author":"Pagani","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0005","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1200\/JCO.18.02433","article-title":"Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows","volume":"37","author":"Regan","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0006","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.03.009_bib0007","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.03.009_bib0008","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2023.03.009_bib0009","article-title":"Deficiencies in immunoassay methods used to monitor serum Estradiol levels during aromatase inhibitor treatment in postmenopausal breast cancer patients","volume":"2","author":"Jaque","year":"2013","journal-title":"Springerplus"},{"key":"10.1016\/j.clbc.2023.03.009_bib0010","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1158\/1055-9965.EPI-06-0765","article-title":"Standardization of steroid hormone assays: why, how, and when?","volume":"16","author":"Stanczyk","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clbc.2023.03.009_bib0011","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2008.18.6213","article-title":"Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial","volume":"27","author":"Rossi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0012","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1200\/JCO.2002.20.4.1026","article-title":"Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer","volume":"20","author":"Harper-Wynne","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0013","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-008-9949-9","article-title":"Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone","volume":"113","author":"Jannuzzo","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2023.03.009_bib0014","first-page":"2261","article-title":"Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study","volume":"19","author":"Celio","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2023.03.009_bib0015","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1016\/j.ejca.2010.08.005","article-title":"Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women","volume":"46","author":"Cheung","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2023.03.009_bib0016","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women","volume":"28","author":"Carlson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1006289811540","article-title":"Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer","volume":"56","author":"Dowsett","year":"1999","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2023.03.009_bib0018","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.18.00296","article-title":"Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial","volume":"37","author":"Dellapasqua","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0019","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1210\/jc.2013-2905","article-title":"Measurement of estradiol\u2013challenges ahead","volume":"99","author":"Stanczyk","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clbc.2023.03.009_bib0020","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-19-3091","article-title":"Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor \u03b1","volume":"26","author":"Ingle","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2023.03.009_bib0021","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.steroids.2007.05.003","article-title":"Superiority of gas chromatography\/tandem mass spectrometry assay (GC\/MS\/MS) for estradiol for monitoring of aromatase inhibitor therapy","volume":"72","author":"Santen","year":"2007","journal-title":"Steroids"},{"key":"10.1016\/j.clbc.2023.03.009_bib0022","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1210\/jc.2005-2378","article-title":"Comparison of methods to measure low serum estradiol levels in postmenopausal women","volume":"91","author":"Lee","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clbc.2023.03.009_bib0023","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2013.53.9411","article-title":"Interpreting plasma estrogen levels in breast cancer: caution needed","volume":"32","author":"Folkerd","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0024","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","article-title":"Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial","volume":"29","author":"Pfeiler","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.03.009_bib0025","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","article-title":"Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial","volume":"30","author":"Ewertz","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923000782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923000782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:25:29Z","timestamp":1761513929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820923000782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1526820923000782"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2023.03.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian Function Suppression in Premenopausal Women With Concurrent Endocrine Therapy Use","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}